skip to main content

Transcatheter Tricuspid Valve Intervention — EECC MCQ

Instant feedback + full explanation. One question, done properly.

ModerateValvular Heart DiseaseTranscatheter Tricuspid Valve InterventionEECC

A 60-year-old man with severe tricuspid regurgitation and RV dysfunction has been referred for transcatheter tricuspid valve intervention (TTVI). What transcatheter options are available for TR?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: E — TEER for the tricuspid valve (TriClip), direct annuloplasty devices, and transcatheter tricuspid valve replacement are emerging options for high-surgical-risk patients with severe symptomatic TR; evidence is growing but remains limited compared with aortic and mitral interventions

Transcatheter tricuspid valve intervention (TTVI) is a rapidly evolving field. Current options include: (1) TEER for TV (TriClip/MitraClip in TV) — edge-to-edge repair reducing TR severity; the TRILUMINATE Pivotal trial showed symptomatic improvement though modest TR reduction; (2) Direct annuloplasty devices (Cardioband) — percutaneous ring annuloplasty; (3) Transcatheter TV replacement (EVOQUE, GATE) — emerging option for severe TR. The 2025 ESC VHD Guidelines include TTVI as a consideration (Class IIb) for severe symptomatic TR in patients at high surgical risk, performed at experienced centres. The evidence base is less mature than for TAVI or mitral TEER, with ongoing trials.

Reference: ESC/EACTS (2025): VHD Guidelines; TRILUMINATE Trial